JGC
ALDX icon

J. Goldman & Co’s Aldeyra Therapeutics ALDX Stock Holding History

J. Goldman & Co’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-27,000
Closed -$180K – 334
2023
Q3 		$180K Sell
27,000
-81,000
-75% -$601K 0.01% 320
2023
Q2 		$906K Buy
108,000
+67,825
+169% +$668K 0.03% 258
2023
Q1 		$399K Sell
40,175
-616,370
-94% -$4.36M 0.02% 284
2022
Q4 		$4.57M Buy
656,545
+323,949
+97% +$1.85M 0.22% 110
2022
Q3 		$1.78M Buy
+332,596
New +$2M 0.08% 219

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

J. Goldman & Co's ALDX Position: Q4 2023 in Review

J. Goldman & Co sold out of Aldeyra Therapeutics (ALDX) in Q4 2023, closing a stake of 27,000 shares — an estimated $180K sold.

J. Goldman & Co first reported a position in ALDX in Q3 2022 and held it in 5 quarters. The position peaked at $4.57M in Q4 2022. 105 funds tracked by Wall St. Rank hold ALDX as of Q4 2023.

  • J. Goldman & Co reported no remaining Aldeyra Therapeutics position as of Q4 2023 after selling out during the quarter.
  • J. Goldman & Co sold 27,000 Aldeyra Therapeutics shares in Q4 2023, an estimated $180K.
  • J. Goldman & Co first reported a position in Aldeyra Therapeutics in Q3 2022 and held it in 5 quarters.
  • J. Goldman & Co's Aldeyra Therapeutics position peaked at $4.57M in Q4 2022.
  • 105 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2023.

Based on J. Goldman & Co's 13F filing for Q4 2023, filed 14 Feb 2024.